Psoriasis appears to be significantly associated with inflammatory bowel disease.
Most studies evaluated fish oil, acupuncture, indigo naturalis, curcumin, meditation.
The final analysis set comprised biologic-naïve individuals — individuals who had filled an initial prescription for etanercept, infliximab, adalimumab, or ustekinumab after 2 years without using any biologic agent during the study period.
Some of the comorbidities include increased lipid levels, hypertension, and diabetes.
Medication-related adverse events occur more frequently with methotrexate in children with moderate to severe psoriasis.
Patients with psoriasis whose disease affects >10% of their body surface area (BSA) are at an increased risk for death compared with the general population.
Sleep complaints among individuals with psoriasis warrant greater clinical attention, as they have a greater chance for developing obstructive sleep apnea.
Patients with psoriasis have a greater risk of mortality due to alcohol-related causes, including alcoholic liver disease, fibrosis and cirrhosis of the liver, and mental and behavioral disorders.
This study shows that more than 50% of patients can expect a 90% or greater improvement in scalp psoriasis within 12 weeks.
Researchers observed a positive correlation between the amount and duration of smoking and the occurrence of psoriasis.
Biosimilar ABP 501 has similar clinical efficacy and safety to adalimumab for the treatment of plaque psoriasis.
Dalazatide treatment reduced the plasma levels of multiple inflammation markers and reduced the expression of T cell activation markers on peripheral blood memory T cells.
The guidelines are the first to provide recommendations for comorbidity screening in pediatric psoriasis patients.
The most common comorbidities found in patients with psoriasis are hyperlipidemia, hypertension, depression, type 2 diabetes mellitus, and obesity.
Researchers sought to analyze long-term and real-world outcome data in patients with moderate-to-severe psoriasis after starting biologic treatment.
Presence of psoriatic arthritis, weight, employment status, baseline disease severity affect the selection of first-line biologic treatment.
Nearly 50% of patients with psoriatic arthritis report elevated levels of fatigue.
The biosimilar has also been approved for Crohn's disease, ulcerative colitis, and ankylosing spondylitis.
Mild, moderate, and severe psoriasis can patients' quality of life and workplace productivity.
Patients with psoriasis are more likely to have an abdominal aortic aneurysm, with the likelihood increasing with more severe psoriasis.
Researchers found that the annual incidence rate of PsA was 2.7 cases per 100 psoriasis patients.
A number of therapeutic options exist for patients with psoriasis, including phototherapy and systemic and biologic agents.
Escalating prices were found across all categories of dermatologic drugs, including anti-infective medications and treatments for psoriasis and rosacea.
Only 10% of Medicare beneficiaries were receiving biologic treatments for psoriasis.
El Nino and La Nina have been linked to increases in actinic keratosis, rosacea, dermatitis, psoriasis, and varicella, among other dermatologic conditions.
Patients with psoriasis or psoriatic arthritis who undergo bariatric surgery may see significant improvements in disease severity.
Biologic agents associated with high risk of hepatitis B virus flares in patients with psoriasis or rheumatoid arthritisNovember 14, 2015
The use of biologic agents in treatment of patients rheumatoid arthritis or psoriasis is associated with a significant risk of heptatis B flares.
Combination use of methotrexate and golimumab may significantly improve psoriatic arthritis symptomsNovember 11, 2015
Using methotrexate and golimumab in combination may significantly improve some symptoms among patients diagnoes with psoriatic arthritis.
Several controlled clinical trials have proven the efficacy of golimumab in reducing symptom severity and improving disease outcomes in patients with psoriatic arthritis.
Many people think that psoriasis is contagious or that it is caused by an infection, which contribute to the stigma.